Evidence and mechanisms for statin-induced cognitive decline.

Biological mechanisms Coenzyme Q HMG-CoA cardiovascular disease cognitive decline side-effects statins

Journal

Expert review of clinical pharmacology
ISSN: 1751-2441
Titre abrégé: Expert Rev Clin Pharmacol
Pays: England
ID NLM: 101278296

Informations de publication

Date de publication:
27 Apr 2019
Historique:
entrez: 30 4 2019
pubmed: 30 4 2019
medline: 30 4 2019
Statut: aheadofprint

Résumé

Statin drugs have become the most highly prescribed drugs for cardiovascular disease. However, there is disagreement as to the existence of adverse effects of statin administration on cognitive function. Therefore, it is important to better understand the effects of statins on cognition and possible mechanisms of these effects. Areas covered: We analyzed relevant studies of the relationship between cognitive performance and statin and usage. We included articles published between 2018 and 1992. We identified three randomized trials, one observational study and 66 case reports that provided credible evidence of statin-induced cognitive impairment. We also identified seven randomized trials and two observational studies reporting no significant evidence of statin-induced cognitive impairment. Expert opinion: We found methodological differences that may have contributed to the divergence of these results. Evaluation of all these studies indicated that statin-associated cognitive decline is a real entity. Likely mechanisms to explain the adverse effects include 1. Reduction of synthesis of coenzyme Q

Identifiants

pubmed: 31030614
doi: 10.1080/17512433.2019.1606711
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1-10

Auteurs

Brendan Tan (B)

a Swinburne Centre for Human Psychopharmacology, Faculty of Health, Arts and Design , Swinburne University of Technology , Melbourne , Australia.

Franklin Rosenfeldt (F)

a Swinburne Centre for Human Psychopharmacology, Faculty of Health, Arts and Design , Swinburne University of Technology , Melbourne , Australia.
b Baker Heart and Diabetes Institute , Melbourne , Australia.

Ruchong Ou (R)

a Swinburne Centre for Human Psychopharmacology, Faculty of Health, Arts and Design , Swinburne University of Technology , Melbourne , Australia.

Con Stough (C)

a Swinburne Centre for Human Psychopharmacology, Faculty of Health, Arts and Design , Swinburne University of Technology , Melbourne , Australia.

Classifications MeSH